Merck Cancer Drug Drives Second-Quarter Sales

Merck’s adjusted earnings for the second quarter beat analysts’ expectations as sales of its cancer drug Keytruda increased 89%.

from WSJ.com: US Business https://ift.tt/2mLEIYP
via IFTTT